Tyvaso DPI: Drug-device characteristics and patient clinical considerations

By sjmartinez • November 16, 2023

McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, Smutney C, Dillon C, Winkler T, Davis B, Broderick M, Burger C. Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Nov 13:102266. doi: 10.1016/j.pupt.2023.102266. Epub ahead of print. PMID: 37967762.

Tags: Cardiology/Epi, Inhaled, prostacyclin, Publications, pulmonary arterial hypertension, pulmonary drug delivery, Pulmonary hypertension with interstitial lung disease, Treprostinil, Veterans Administration

Diesel exhaust induces gut microbiome dysbiosis and reduced fecal acetate: Role of acetate supplementation

Gupta R, Chang C, Vergnes L, Sulaiman D, Yin F, Stewart JA, Mehrabian M, Kaufman JD, Jacobs JP, Lusis AJ, Reue K, Rosenfeld ME, Araujo[...]

Non-cardiovascular Calcification Measures and Warranty Period of a Zero CAC in Young Adults: the Multi-ethnic Study of Atherosclerosis

Ghotbi E, Nasir K, Bancks MP, Subhas N, Akhtarkhavari S, Shabani M, Hadidchi R, Bluemke DA, Post WS, Budoff M, Graham Barr R, Lima JAC,[...]

Artificial-intelligence-assisted CCTA quantifies sex differences in coronary atherosclerotic burden at low atheroma volumes

D'Costa Z, Karlsberg RP, Cho GW. Artificial-intelligence-assisted CCTA quantifies sex differences in coronary atherosclerotic burden at low atheroma volumes. Int J Cardiol Heart Vasc. 2025[...]